stock-detail (OXGN)

Oncology Corporate Profile

This company does not have any commercial products
  • Brand
  • Generic
  • Investigational
Brand / Product Class Area of Study Phase Partnership
Zybrestat® / fosbretabulinvascular disrupting agentAnaplastic Thyroid cancerIII
Zybrestat® / fosbretabulinvascular disrupting agentGastric cancerII
Zybrestat® / fosbretabulin (+ bevacizumab)vascular disrupting agentGlioblastoma Multiforme (GBM)II
Zybrestat® / fosbretabulinvascular disrupting agentNon Small Cell Lung Cancer (NSCLC)II
Zybrestat® / fosbretabulin (+ bevacizumab)vascular disrupting agentOvarian cancerII
Zybrestat® / fosbretabulinvascular disrupting agentPlatinum-sensitive Ovarian cancerII
OXi4503vascular disrupting agentAcute Myelogenous Leukemia (AML)I
OXi4503vascular disrupting agentMyelodysplastic Syndrome (MDS)I
Zybrestat® / fosbretabulin (+ pazopanib)vascular disrupting agentOvarian cancerI

Recent News Headlines

New Therapeutic Target in Myeloma Discovered

3/8/2016 11:02 am

(Mount Sinai) Mar 7, 2016 - A new study by researchers at The Tisch Cancer Institute at the Icahn School of Medicine at Mount Sinai has shown that targeting both CDK4 and ARK5, proteins responsible for maintaining energy balance within the cell, was extremely effective in causing cell death in myeloma.

QOPI Certification and QOPI Participation Now Recognized by the ABIM for Maintenance of Certification

2/26/2016 11:05 am

(ASCO in Action) Feb 25, 2016 - The American Board of Internal Medicine (ABIM) has approved Maintenance of Certification (MOC) points for physicians whose practices have received accreditation through ASCO's Quality Oncology Practice Initiative (QOPI®) Certification Program (QCP™).

Study Provides Consensus on Association Between Allergies and Glioma Risk

2/5/2016 11:03 am

(Baylor College of Medicine) Feb 5, 2016 - Researchers found an inverse association between allergies, asthma and eczema and a brain cancer called glioma, meaning that people who have the allergic conditions may be less likely to develop the brain cancer.

Cancer MoonShot 2020 Holds First Coalition Meeting: Inaugural Retreat of Thought Leaders from Government, Healthcare, Biotech, Scientific and Technology Communities Unify on Immediate Next Steps in the War on Cancer

1/25/2016 11:03 am

(Yahoo! Finance) Jan 25, 2016 - Consensus reached on implementation of the Three Pillars of Cancer MoonShot 2020 Program: panomic, whole genomic and proteomic analysis; big data, predictive analytics, and interoperability; and a single platform to guide novel combination immunotherapeutic interventions of more than 20 immunotherapy combination protocols.

TG Therapeutics, Inc. Launches Phase 1/2 "Triple-Therapy" Study With TGR-1202 + TG-1101 + the PD-1 Checkpoint Inhibitor Pembrolizumab in Patients With Advanced Chronic Lymphocytic Leukemia (CLL) at the University of Pennsylvania's Abramson Cancer Center

9/9/2015 11:00 am

(MarketWatch) Sept 9, 2015 - TG Therapeutics, Inc. today announced the initiation of a Phase 1/2 clinical study that will investigate the use of TGR-1202, the Company's oral PI3K delta inhibitor and TG-1101 (ublituximab), the Company’s glycoengineered anti-CD20 monoclonal antibody in combination with pembrolizumab the anti-PD-1 immune checkpoint inhibitor, in patients with relapsed or refractory CLL.

Genmab Announces European Regulatory Submission for Daratumumab in Double Refractory Multiple Myeloma

9/9/2015 11:00 am

(CNNMoney) Sept 9, 2015 — Genmab A/S announced today that Janssen-Cilag International NV (Janssen) has submitted a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for daratumumab.

Personalized Medicine’s Success Depends on Pathologist’s Ability to Make Accurate Histologic and Genetic Classification of Tumors

9/9/2015 11:00 am

(IASLC) Sept 8, 2015 - If cancer patients are to receive optimal treatment, clinicians must have an accurate histologic classification of the tumor and know its genetic characteristics, said William D. Travis, M.D., attending thoracic pathologist, Department of Pathology, at Memorial Sloan Kettering Cancer Center in New York City. Dr. Travis made his remarks today at the 16th World Conference on Lung Cancer (WCLC) hosted by the International Association of the Study of Lung Cancer (IASLC).

Scope of Lymphadenectomy Not Tied to Esophageal CA Survival

9/9/2015 10:05 am

(Physician’s Briefing/HealthDay News) Sept 4, 2015 - For patients undergoing esophageal cancer surgery, the extent of lymphadenectomy seems not to influence all-cause or disease-specific survival, according to a study published online Sept. 2 in JAMA Surgery.

Pancreatic Cancer Subtypes Discovered in Largest Gene Expression Analysis of the Disease to-Date

9/9/2015 10:05 am

(UNC) Sept 7, 2015 - Dense surrounding tissue can block drugs from reaching pancreatic cancer tumors, but it also can help prevent the cancer from spreading. New research led by members of the UNC Lineberger Comprehensive Cancer Center helps explain the conflicting role of the surrounding tissue, known as stroma.

Five Prime Therapeutics Initiates Patient Dosing in Phase 1a/1b Trial Evaluating the Immunotherapy Combination of FPA008 and OPDIVO (nivolumab) in Six Tumor Types

9/9/2015 10:05 am

(StreetInsider) Sept 8, 2015 - Five Prime Therapeutics, Inc. today announced that it has initiated patient dosing in the Phase 1a/1b clinical trial evaluating the immunotherapy combination of FPA008, Five Prime's monoclonal antibody that inhibits colony stimulating factor-1 receptor (CSF1R), with OPDIVO(R) (nivolumab), Bristol-Myers Squibb's PD-1 immune checkpoint inhibitor, in six tumor types.

Aduro Biotech Completes Enrollment in Phase 2b ECLIPSE Trial in Metastatic Pancreatic Cancer

9/9/2015 10:05 am

(Aduro Biotech) Sept 8, 2015 - Aduro Biotech, Inc. today announced that it has completed enrollment in the Phase 2b ECLIPSE trial of its novel LADD and GVAX immunotherapies being developed for the treatment of metastatic pancreatic cancer.

Seattle Genetics Completes Enrollment in Phase 3 ALCANZA Clinical Trial Evaluating ADCETRIS(R) (Brentuximab Vedotin) in CD30-Expressing Cutaneous T-Cell Lymphoma (CTCL)

9/9/2015 10:05 am

(Seattle Genetics) Sept 9, 2015 - Results from two investigator-sponsored phase 2 clinical trials recently published in the journal of clinical oncology evaluating Adcetris in patients with relapsed CTCL demonstrate 70 percent or greater objective response rate; ALCANZA data anticipated in second half of 2016.

Aduro Biotech Announces Clinical Trial Agreement to Evaluate Combination of Two Novel Cancer Immunotherapies for the Treatment of Ovarian Cancer

9/9/2015 10:05 am

(The Street) Sept 9, 2015 - Aduro Biotech, Inc. announced today that it has entered into a clinical trial agreement with Incyte Corporation to evaluate the safety, tolerability and preliminary efficacy of Aduro's lead LADD immunotherapy, CRS-207, in combination with Incyte's oral indoleamine dioxygenase 1 (IDO1) inhibitor, epacadostat (INCB24360), in patients with ovarian cancer.

OncoMed Pharmaceuticals Announces Presentation of Tarextumab Small Cell Lung Cancer Data at the 16th World Conference on Lung Cancer

9/9/2015 10:04 am

(StreetInsider) Sept 9, 2015 - OncoMed Pharmaceuticals Inc. reported new biomarker and updated clinical data for the company's Phase 2 anti-Notch2/3 therapeutic candidate, tarextumab (OMP-59R5).

Study Defines Criteria for MET-Driven Lung Cancer Suitable for Crizotinib Treatment

9/9/2015 10:04 am

(UCCC/Colorado Cancer Blog) Sept 8, 2015 - A University of Colorado Cancer Center study being presented today at the 16th World Conference on Lung Cancer in Denver, Colorado sheds light on the best method to determine the threshold at which MET amplification becomes clinically relevant.

Myriad Adds to Scientific Evidence for the myPlan® Lung Cancer Prognostic Test

9/9/2015 10:04 am

(TheStreet) Sept 9, 2015 – Myriad Genetics, Inc. today presented two posters on its myPlan® Lung Cancer prognostic test at the International Association for the Study of Lung Cancer (IASLC) 16TH World Conference on Lung Cancer being held in Denver, Colo.

Increased Detection Of Low-Risk Tumors Driving Up Thyroid Cancer Rates

9/9/2015 10:04 am

(Mayo Clinic) Sept 8, 2015 - Low-risk cancers that do not have any symptoms and presumably will not cause problems in the future are responsible for the rapid increase in the number of new cases of thyroid cancer diagnosed over the past decade, according to a Mayo Clinic study published in the journal Thyroid.

Roche Wins Priority FDA Review for Experimental Lung Cancer Drug

9/9/2015 10:03 am

(Bloomberg) Sept 9, 2015 - Roche Holding AG’s experimental drug alectinib will be fast-tracked by U.S. regulators to treat a form of aggressive lung cancer that has spread.

U.S. FDA Grants Priority Review to Takeda’s Ixazomib for Patients with Relapsed/Refractory Multiple Myeloma

9/9/2015 10:03 am

(Millennium) Sept 9, 2015 – Takeda Pharmaceutical Company Limited today announced that the U.S. Food and Drug Administration (FDA) has granted Priority Review status to the New Drug Application (NDA) for ixazomib, the first investigational oral proteasome inhibitor for the treatment of patients with relapsed and/or refractory multiple myeloma.

Giant Study Boosts Januvia, Merck's $6 Billion Drug

6/9/2015 12:02 pm

(Forbes) June 8, 2015 - Januvia, a widely used diabetes drug that generates $6 billion in annual sales for maker Merck, does not increase patients’ risk of being hospitalized for heart failure, a risk that did show up in clinical trials of competing drugs.

MetaStat Demonstrates MenaCalc Lung™ Is Prognostic for Outcome in Non-Small Cell Lung Cancer

4/21/2015 12:05 pm

(TheStreet) Apr 21, 2015 - MetaStat, Inc., a molecular diagnostic company focused on developing and commercializing epigenetic-based diagnostic tests for early and reliable prediction of systemic metastasis, today presented the positive results of a clinical study demonstrating the MenaCalc Lung™ score is an independent prognostic factor and predictive for distant metastasis in patients with non-small cell lung cancer at the annual meeting of the American Association for Cancer Research (AACR) in Philadelphia.

Measuring Response to Leukemia Treatment May Save More Lives

3/23/2015 12:00 pm

(St. Jude Children's) Mar 20, 2015 - Measuring the concentration of leukemia cells in patient bone marrow during the first 46 days of chemotherapy should help boost survival of young leukemia patients by better matching patients with the right intensity of chemotherapy.

ASCO to Hold Capitol Hill Briefing March 17 to Release State of Cancer Care in America: 2015

3/12/2015 11:05 am

(ASCO) Mar 11, 2015 - The State of Cancer Care in America: 2015 report, to be released on March 17 by the American Society of Clinical Oncology (ASCO), chronicles the current realities of the cancer care delivery system in the United States and examines trends in the oncology workforce and practice environment that are affecting patient care and access.

Combining Newer, More Intensive First-Line Chemotherapy With Bevacizumab Improves Long-Term Outcome in Advanced Colorectal Cancer

1/13/2015 11:02 am

(ASCO) Jan 12, 2015 - Updated results from TRIBE, an Italian phase III study of patients with metastatic colorectal cancer, indicate that FOLFOXIRI chemotherapy in combination with bevacizumab is superior to the standard FOLFIRI chemotherapy with bevacizumab.

Oxigene CEO Quits, Chaplin Takes Helm

5/16/2014 07:00 am

(San Francisco Business Times/Biotech SF blog) May 16, 2014 - Drug company Oxigene Inc. hired David Chaplin as CEO, taking over from Peter Langecker, M.D.